The drive to identify genetic factors influencing left ventricular mass responses to antihypertensive treatment

Journal of Hypertension

Volumn 20, Issue 4, 2002, Pages 583-585

  Fagard, Robert H ^a   Kuznetsova, Tatiana ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN;

ALLELE; ANTIHYPERTENSIVE THERAPY; EDITORIAL; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEART HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEREDITY; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0036528727     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200204000-00007     Document Type: Editorial

References (34)

1. Prognostic implications of left ventricular hypertrophy
2. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension
3. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
4. Prognostic significance of serial changes in left ventricular mass in essential hypertension
5. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies
6. Reversibility of left ventricular hypertrophy by antihypertensive drugs
7. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: The prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial
8. 1-receptor gene are related to change in left ventricular mass during antihypertensive treatment
9. Tissue renin-angiotensin system in myocardial hypertrophy and failure
10. Tissue renin-angiotensin system: Sites of angiotensin formation
11. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
12. Molecular basis of human hypertension: Role of angiotensinogen
13. Angiotensin II type-1 receptor gene polymorphisms in human essential hypertension
14. A chlmaeric 11 b-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
15. Antihypertensive treatment modulates the association between the DII ACE gene polymorphism and left ventricular hypertrophy: A metaanalysis
16. Angiotensin-converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction
17. Variants of renin-angiotensin system genes and echocardiographic left ventricular mass
18. Angioten-sinogen gene M235T and T174M polymorphisms in essential hypertension. Relation with target organ damage
19. Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension
20. Synergistic effect of angiotensin-converting enzyme and angiotensinogen gene on cardiac hypertrophy
21. ACE and angiotensinogen gene genotypes and left ventricular mass in athletes
22. Haplotypes of angiotensinogen in essential hypertension
23. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
24. 1166 polymorphism. Relationships with blood pressure and cardiovascular structure
25. Association of angiotensin converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries
26. Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension
27. The product of the CYP11 B2 gene is required for aldosterone biosynthesis in the human adrenal cortex
28. Associations between the human aldosterone synthase (CYP11B2) gene polymorphism and left ventricular size, mass, and function
29. Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure
30. Pharmacogenomics: Translating functional genomics into rational therapeutics
31. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies
32. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors
33. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism
34. Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension